Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain … (NCT04459234) | Clinical Trial Compass
CompletedNot Applicable
Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC
France81 participantsStarted 2021-02-02
Plain-language summary
The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication).
The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression.
In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient at least 18 years old at the day of consenting to the study
* Patient followed for a solid tumour or a hematological malignancy (treated or under treatment)
* Patient presenting cancer chronic pain or post cancer treatment pain
* Patient followed by a CLCC's intractable chronic pain consultation or centre
* Patient with an indication of 1st Ketamine course:
* Analgesic treatment of cancer chronic pain
* Analgesic treatment for a post-cancer treatment chronic pain
* Help for withdrawal from opioid treatment prescribed for a chronic cancer pain
* Patient not previously treated by Ketamine
* Patient covered by a medical insurance
* Patient and/or family did not decline data collection after complete information (information sheet)
Exclusion Criteria:
* Patient presenting chronic pains not related to cancer or its treatments
* Patient with a proven psychotic history
* Patient who is not fluent enough in French
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication
Timeframe: Up to 3 months after inclusion
2
Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of administration protocol